Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$275,000.00

Bulk and single cell molecular profiling of matched primary and recurrent glioblastoma

EF 2017-18

Résumé
Glioblastoma (GBM) is the most common and lethal adult primary brain tumor. Despite maximal treatment with surgery, chemotherapy, and radiation, GBM will inevitably recur, on average approximately 16 months after treatment, and unfortunately, there are no standard treatment options available for patients after recurrence. It has been suggested that the genetic composition of the recurrent tumor may be different than the initial tumor, which, If true, would have implications for potential new treatments options available for recurrent GBM that would not be available for the primary tumor. As such, we propose to perform in-depth genomic analyses of primary and matched recurrent GBM at a bulk and single cellular level. Our approach will 1) improve our understanding of the cellular composition of recurrent GBM, 2) allow us to identify genetic drivers of tumor recurrence and 3) potentially identify novel therapeutic targets for treatment of recurrent GBM.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
377077
Name
Nassiri Farshad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Bulk and single cell molecular profiling of matched primary and recurrent glioblastoma
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$275,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Bioinformatics; Brain Cancer; Genetics; Genomics; Glioblastoma; Glioma
Abstract
Glioblastoma (GBM) is the most common and lethal adult primary brain tumor. Despite maximal treatment with surgery, chemotherapy, and radiation, GBM will inevitably recur, on average approximately 16 months after treatment, and unfortunately, there are no standard treatment options available for patients after recurrence. It has been suggested that the genetic composition of the recurrent tumor may be different than the initial tumor, which, If true, would have implications for potential new treatments options available for recurrent GBM that would not be available for the primary tumor. As such, we propose to perform in-depth genomic analyses of primary and matched recurrent GBM at a bulk and single cellular level. Our approach will 1) improve our understanding of the cellular composition of recurrent GBM, 2) allow us to identify genetic drivers of tumor recurrence and 3) potentially identify novel therapeutic targets for treatment of recurrent GBM.
Competitiondate
201711
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Nassiri, Farshad
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $275,000~ $0~